Drop in clin­i­cal tri­al num­bers un­der­scores drug­mak­er­s' fears over Brex­it that trace back over a year

A week ago, Re­car­dio an­nounced it would cut UK tri­al sites out of its up­com­ing heart drug study cit­ing Brex­it fears that quick­ly re­ver­ber­at­ed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.